Marché de l’immunohématologie en Arabie saoudite, en Turquie et en Égypte – Tendances et prévisions de l’industrie jusqu’en 2030

Analyse et perspectives du marché de l'immunohématologie en Arabie saoudite, en Turquie et en Égypte 

Le marché de l'immunohématologie en Arabie saoudite, en Turquie et en Égypte devrait croître au cours de l'année de prévision en raison d'une augmentation du nombre de lancements de produits avec l'innovation et les progrès technologiques pour répondre aux besoins du marché devraient favoriser la croissance du marché. Les principaux acteurs du marché sont de plus en plus intéressés par l'utilisation de nouvelles technologies pour attirer l'attention de l'utilisateur final. L'utilisation de kits ou d'instruments de détermination du groupe sanguin et de dépistage des anticorps connaît une croissance rapide et offre une formidable opportunité dans ce secteur. Par conséquent, la demande de produits d'immunohématologie augmente en raison de la prévalence croissante des incidents de traumatisme et des troubles d'immunohématologie dans le monde. Cependant, le manque de professionnels qualifiés pour effectuer des tests d'hématologie peut entraver la croissance du marché.

Le marché de l'immunohématologie en Arabie saoudite, en Turquie et en Égypte devrait connaître une croissance du marché au cours de la période de prévision de 2023 à 2030. Data Bridge Market Research analyse que le marché croît avec un TCAC de 3,8 %, 4,2 % et 3,0 % au cours de la période de prévision de 2023 à 2030, respectivement pour la Turquie, l'Arabie saoudite et l'Égypte.  

Définition du marché

A subfield of medicine called immunohematology studies how the immune system interacts with blood, specifically identifying blood cell antigens and associated antibodies. It covers the theories and clinical methods involved in contemporary transfusion therapy. Blood transfusion attempts to save human lives have been documented for several centuries.

RBCs contain more than 230 different types of antigens, which can be divided into two main categories based on their chemical makeup: carbohydrates and polypeptides. If the genes are known and found on nearby loci, they are categorized in blood group systems, and if the genes responsible for their formation have not yet been identified, they are categorized in blood group collections. Specific genes that are inherited from parents are responsible for the RBC antigen formation. Because an ABO mismatch can be lethal, the ABO blood group system, which was the first to be identified at the turn of the 20th century, is still regarded as the most significant antigenic system. However, the High cost of hematology instruments, reagents and kits and standards for the approval and commercialization of products is expected to restrain the market growth.

Saudi Arabia, Turkey and Egypt Immunohematology Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:

Drivers

• Increasing demand for blood and blood products

Most patients who have a major surgical procedure will have a blood transfusion to replace any blood loss during their surgery. Blood transfusions are used for patients who have experienced serious injuries from car crashes or natural disasters. Individuals with an illness that causes anemia, such as leukemia or kidney disease, will often be the recipients of blood transfusions.

Thus, the increasing demand for blood and blood products is expected to accelerate the growth of the immunohematology market significantly in the nearby future.

• Technological advancements for the development of new products

Since the discovery of the ABO system, numerous important innovations have contributed to a continuous, rapid evolution in the diagnostic methods for in vitro measurements of the antigen-antibody reaction, allowing a significant improvement in the compatibility between blood from donors and recipients.

Apart from the introduction of ABO typing, these methods include the determination of Rh type and phenotype, the direct and indirect antiglobulin tests, cross-matching and consequent identification of antigens and antibodies of clinical relevance, the use of low ionic strength additives and enzyme treatments, the development of monoclonal reagents and solid-phase and microcolumn platforms for performing the pre-transfusion tests.

Thus, technological advancements for the development of new products is expected to drive market growth.

Opportunities

• Rising awareness about blood donation

Blood donations can yield a variety of blood products, including red cells, platelets and plasma. You may be most familiar with the typical whole blood donation drive seen at workplaces, schools and community events, but there are a few other ways to help give more life through the Red Cross. For cancer patients, blood transfusions can act as a resource to implement platelets back into the body after heavy treatments such as chemo or radiation therapy.

Therefore, a rise in awareness about blood donation is further expected to create a lot of opportunities for the market to grow.

• Rising cases of blood cancer

Blood cancer is a type of cancer that affects the blood cells. Leukaemia, lymphoma and myeloma are some of the most common types of blood cancer. There are also types called MPNs and MDS. Blood cancer is caused by changes (mutations) in the DNA within blood cells. This causes the blood cells to start behaving abnormally. Thus, rising cases of blood cancer is expected to act as an opportunity for market growth in the coming years.

Restraints/Challenges

• High Cost of blood testing and transfusion

The transfusion is a burden for both the hospital management systems and the country's economy. To accurately calculate and manage this economic burden is important for sustainable healthcare services. Allogeneic blood transfusion causes variable costs according to different applications in treatment expenditures. It imposes an economic burden to purchase, test and prepare the component suitable for transfusion, deliver blood components to relevant clinics, apply to the recipient, monitor and treat transfusion-induced reactions, dispose of it as medical waste, and file all mandatory information.

Hence, the high cost of blood testing and transfusion, which is further restraining the growth of the market to an extent. 

• Risk of transfusion- transmitted infections

Transfusion-transmitted infections (TTIs) are infections resulting from the introduction of a pathogen into a person through blood transfusion. A wide variety of organisms, including bacteria, viruses, prions, and parasites, can be transmitted through blood transfusions.

Bacterial contamination of blood products, especially in platelets stored at room temperature, is the most common infectious risk of blood transfusion, occurring in approximately 1 in every 2,000-2,500 platelet transfusions. Transfusion–transmitted sepsis, while less common, can cause severe illness and death. Improved donor screening and improved methods of collection, handling, and storing of blood products have decreased bacterial contamination in recent years.

For instance,

• In December 2022, according to the information provided by National Center for Biotechnology Information (NCBI), Hepatitis B virus, HCV, and syphilis carry the greatest risk of transfusion-transmittable infection (TTI) in Saudi Arabia. Including HBsAg screening is a necessary precautionary measure to maintain blood safety

Hence the risk of transfusion transmitted infections will act as a challenge to the market.

Recent Development

• In August 2022, Bio-Rad Laboratories, Inc. announced that the company acquired Scope Fluidics, S.A., a Warsaw, Poland-based developer of cutting-edge technology solutions for the medical diagnostic and healthcare markets, has agreed to sell all of Curiosity Diagnostics, Sp. Z. o. o.'s outstanding shares to Bio-Rad Laboratories, Inc. for a total consideration of up to $170 million, consisting of roughly $100 million in cash and up to $70 million in potential future milestone payments. A sample-to-answer, rapid diagnostics PCR system is being developed by Curiosity Diagnostics, a late-stage, pre-commercial platform firm, for the molecular diagnostics market. This prompted the company to grow its clientele.
• In July 2022, Beckman Coulter, Inc. announced a partnership with Scopio in order to hasten the deployment of their most recent platforms for peripheral blood smears. In order to completely replace manual microscopy, Scopio's technology uses Full-Field imaging and AI decision support while offering laboratory workers and doctors a genuine workflow boost. The Scopio systems streamline lab operations and enhance workflow in a distributed network with easy-to-use remote viewing. No longer must slides be sent between locations; high quality full-field images may now be transmitted in real time across a secure hospital network. This has aided the corporation in using modern technology to grow its operations.

Saudi Arabia, Turkey, and Egypt Immunohematology Market Scope

Saudi Arabia, Turkey, and Egypt immunohematology market is segmented into five notable segments such as product type, technology, application, end user and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Product Type

• Immunohematology Analyzer
• Immunohematology Reagent

On the basis of product type, Saudi Arabia, Turkey, and Egypt immunohematology market is segmented into immunohematology analyzer and immunohematology reagent.

Technology

• Microplates
• Gel Cards
• Erythrocyte Magnetized Technology (EMT)
• Polymerase Chain Reaction
• Others

On the basis of technology, the Saudi Arabia, Turkey, and Egypt immunohematology market is segmented into microplates, gel cards, erythrocyte magnetized technology (EMT), polymerase chain reaction and others.

Application

• Antibody Screening
• Blood Typing

On the basis of application, the Saudi Arabia, Turkey, and Egypt immunohematology market is segmented into antibody screening and blood typing.

End User

• Blood banks
• Hospitals
• Diagnostics and Reference Laboratories
• Academic and Research Institutes

Sur la base de l'utilisateur final, le marché de l'immunohématologie d'Arabie saoudite, de Turquie et d'Égypte est segmenté en banques de sang, hôpitaux, laboratoires de diagnostic et de référence, et instituts universitaires et de recherche.

Canal de distribution

• Vente directe
• Ventes au détail
• Distribution par des tiers

Sur la base du canal de distribution, le marché de l'immunohématologie d'Arabie saoudite, de Turquie et d'Égypte est segmenté en ventes directes, ventes au détail et distribution à des tiers.

Analyse/perspectives régionales du marché de l'immunohématologie en Arabie saoudite, en Turquie et en Égypte      

Le marché de l’immunohématologie est analysé et des informations et tendances sur la taille du marché sont fournies par pays, type de produit, technologie, application, utilisateur final et canal de distribution.

Analyse du paysage concurrentiel et des parts de marché de l'immunohématologie en Arabie saoudite, en Turquie et en Égypte

Le paysage concurrentiel du marché de l'immunohématologie fournit des détails sur les concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise sur le marché de l'ataxie.

Certains des principaux acteurs opérant sur le marché de l'immunohématologie en Arabie saoudite, en Turquie et en Égypte sont Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., Abbott, F. Hoffmann-La Roche Ltd, Ortho Clinical Diagnostics, Boule, Merck KGaA, Beckman Coulter, Inc., Abbott, Bio-Rad Laboratories, Inc., HORIBA et entre autres.

SKU-69930